|
Keegan,
P., Loughman, B.E. “Early Clinical Trials of Chemopreventive
and Biologic Agents: Designs, Populations, and
Endpoints” (2001) Urology
57 (4
Suppl 1):216-219.
Myers,
C., Koki, A., Pamukcu, R., Wechter, W., Padley,
R.J. “Proapoptotic Anti-inflammatory Drugs” (2001)
Urology 57 (4 Suppl 1):73-76.
Lilly M,
Ruckle H, Quiggle DD, Gutierrez I, Murray Jr. ED,
Gibson KM, Leipold DD, Wechter WJ, Loughman BE.
"Multi-dose phase I-II trial of E-7869 in prostate
cancer patients: safety and time to PSA progression
(TPSAP)." (2001) Proceedings of AACR 42:142.
Quiggle D.D., Lilly
M., Murray Jr. E.D., Gibson K.M., Leipold DD,
Gutierrez I., Loughman B.E., Wechter W.J. PK "Guided
Multi-dose, Tolerance and Safety of E-7869 in
Prostate Cancer Patients." (2000) Proceedings
of AACR 41:609.
Murray
Jr., E.D., Quiggle, DD, Gibson, K.M., Leipold, DD,
Loughman, B.E., Wechter, W.J. "Phase I Single-dose
Pharmacokinetics and Lack of Enantiomeric Bioinversion
of E-7869 (R-flurbiprofen)." (2000) Clinical
Pharmacology and Therapeutics Vol. 67, No. 2,
103.
Swabb EA,
Quiggle DD, Gutierrez I, Murray Jr. ED, Reid JE,
Wechter WJ, Loughman BE. "Multi-dose Phase
IIa Trial of MPC-7869 in Prostate Cancer Patients
with Increasing Prostate Specific Antigen (PSA)"
(2002) Proceedings of AACR 43:749.
|
